Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients diagnosed with NSCLC have a poor prognosis, with a 5-year survival rate of only 16 percent. Researchers hope to improve NSCLC patient survival with the results of a study that found that inherited genetic variations in interleukin genes are associated with improved patient survival and response to therapy.